Slingshot members are tracking this event:
Phase 3 data of AbbVie's(ABBV) Risankizumab in Psoriasis due by the end of 2017 due by the end of 2017
Slingshot Insights Explained
Oct 26, 2017
Don’t see a project related to the catalyst you care about?
Related Keywords Phase Iii Study, Risankizumab, Psoriasis